Back
 JBM  Vol.4 No.12 , December 2016
An Unusual and Previously Unreported Association between Tyrosinemia Type 1 and an Extremely Rare Variation of Congenital Cystic Dilatation: TODANI’s VI Cystic Duct Cyst: Report of a Case
Abstract: Cystic duct cysts are rare lesions, and type VI of TODANI’s modified classification is the rarest subtype with only sporadic case reports in the literature. The following report describes the coexistence of this entity and type 1 tyrosinemia in a one month-old infant referred to our department for etiological investigations of prolonged neonatal cholestasis. To the best of our knowledge, we report herein the first case in the literature describing this association. Cystic duct abnormalities should be considered in the differential diagnosis of neonatal cholestases, however further investigations should be performed to exclude associated life-threatening conditions such as metabolic disorders including tyrosinemia.
Cite this paper: Essabar, L. , Rghouda, H. , Dahri, S. , Chabraoui, L. , Chat, L. and Kriouile, Y. (2016) An Unusual and Previously Unreported Association between Tyrosinemia Type 1 and an Extremely Rare Variation of Congenital Cystic Dilatation: TODANI’s VI Cystic Duct Cyst: Report of a Case. Journal of Biosciences and Medicines, 4, 126-131. doi: 10.4236/jbm.2016.412016.
References

[1]   Bode, W.E. and Aust, J.B. (1983) Isolated Cystic Dilatation of the Cystic Duct. The American Journal of Surgery, 145, 828-829.
https://doi.org/10.1016/0002-9610(83)90152-6

[2]   Conway, W.C., Telian, S.H., Wasif, N. and Gagandeep, S. (2009) Type VI Biliary Cyst: Report of a Case. Surgery Today, 39, 77-79.
https://doi.org/10.1007/s00595-008-3789-4

[3]   Dumitrascu, T., Lupescu, I. and Ionescu, M. (2012) The Todani Classification for Bile Duct Cysts: An Overview. Acta chirurgica Belgica, 112, 340-345.
https://doi.org/10.1080/00015458.2012.11680849

[4]   Serena Serradel, A.F., Santamaria, L.E. and Herrera, G.R. (1991) Cystic Dilatation of the Cystic Duct: A New Type of Biliary Cyst. Surger, 109, 320-322.

[5]   de Laet, C., Carlo, D.V., James, V.L., et al. (2013) Recommendations for the Management of Tyrosinaemia Type 1. Orphanet Journal of Rare Diseases, 8, 8.
https://doi.org/10.1186/1750-1172-8-8

[6]   Todani, T., Watanabe, Y., Nanisue, M., et al. (1977) Congenital Bile Duct Cysts: Classification, Operative Procedures, and Review of Thirty-Seven Cases Including Cancer Arising from Choledochal Cyst. The American Journal of Surgery, l34, 263-269.

[7]   Loke, T., Lam, S. and Chan, C. (1999) Choledochal Cyst: An Unusual Type of Cystic Dilatation of the Cystic Duct. American Journal of Roentgenology, 173, 619-620.
https://doi.org/10.2214/ajr.173.3.10470889

[8]   Yoon, J.H. (2011) Magnetic Resonance Cholangiopancreatography Diagnosis of Choledochal Cyst Involving the Cystic Duct: Report of Three Cases. British Journal of Radiology, 84, 18-22.
https://doi.org/10.1259/bjr/77844300

[9]   De Vries, J.S., de Vries, S., Aronson, D.C., Bosman, D.K., Rauws, E.A., Bosma, A., et al. (2002) Choledochal Cysts: Age of Presentation, Symptoms, and Late Complications Related to Todani’s Classification. Journal of Pediatric Surgery, 37, 1568-1573.
https://doi.org/10.1053/jpsu.2002.36186

[10]   Todani, T., Tabuchi, K., Watanabe, Y. and Kobayashi, T. (1979) Carcinoma Arising in the Wall of Congenital Bile Duct Cysts. Cancer, 44, 1134-1141.
https://doi.org/10.1002/1097-0142(197909)44:3<1134:
:AID-CNCR2820440350>3.0.CO;2-T

[11]   Rashad, M.M. and Nassar, C. (2011) Tyrosinemia Type 1: A Case Report. Sudanese Journal of Paediatrics, 11, 64-67.

[12]   Mayorandan, S., Meyer, U., Gokcay, G., Segarra, N.G., et al. (2014) Cross-Sectional Study of 168 Patients with Hepatorenal Tyrosinaemia and Implications for Clinical Practice. Orphanet Journal of Rare Diseases, 9, 107.
https://doi.org/10.1186/s13023-014-0107-7

[13]   Sander, J., Janzen, N., Peter, M., Sander, S., Holtkamp, U., Schwahn, B., Mayatepek, E., Trefz, F.K. and Das, A.M. (2006) Newborn Screening or Hepatorenal Tyrosinemia: Tandem Mass Spectrometric Quantification of Succinylacetone. Clinical Chemistry, 52, 482-487.
https://doi.org/10.1373/clinchem.2005.059790

[14]   Baumann, U., Preece, M.A., Green, A., Kelly, D.A. and McKiernan, P.J. (2005) Hyperinsulinism in Tyrosinaemia Type I. Journal of Inherited Metabolic Disease, 28, 131-135.
https://doi.org/10.1007/s10545-005-5517-1

[15]   Van Spronsen, F.J., Thomasse, Y., Smit, G.P., Leonard, J.V., Clayton, P.T., Fidler, V., Berger, R. and Heymans, H.S. (1994) Hereditary Tyrosinemia Type I: A New Clinical Classification with Difference in Prognosis on Dietary Treatment. Hepatology, 20, 1187-1191.
https://doi.org/10.1002/hep.1840200513

[16]   Masurel-Paulet, A., Poggi-Bach, J., Rolland, M.O., Bernard, O., et al. (2008) NTBC-Treatment in Tyrosinaemia Type I: Long-Term Outcome in French Patients. Journal of Inherited Metabolic Disease, 31, 81-87.
https://doi.org/10.1007/s10545-008-0793-1

[17]   Coskun, T., Ozalp, I., Kocak, N., Yüce, A., Caglar, M. and Berger, R. (1991) Type I Hereditary Tyrosinaemia: Presentation of 11 Cases. Journal of Inherited Metabolic Disease, 14, 765-770.
https://doi.org/10.1007/BF01799947

 
 
Top